The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol--the so-called "bad" cholesterol--by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found.

Largest study on how cannabis has changed over time finds increased strength putting consumers at greater risk of harm

New study identifies a region of the thalamus as a key source of signals encoding past experiences in the neocortex.

Features of the SARS-CoV-2 virus causing COVID-19, which could be useful for developing vaccines and treatment strategies, were identified using a nonhuman primate model developed at the Korea Research Institute of Bioscience and Biotechnology(KRIBB).

This randomized trial examines the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk.

Omega-3 supplements in commonly available forms appear to be ineffective in preventing further cardiovascular events among elderly people with recent heart attacks.When compared to a placebo, an omega-3 fatty acids supplement in addition to statin therapy and/or a blood thinner did not reduce the number of cardiac events in a study of more than 1,000 patients in Norway.

People taking dummy pills and statins experienced similar side effects in a new study.

Laser writing breathes life into high-performance sensing platforms.

Study participants who reported side effects from cholesterol-lowering medications known as statins also reported the same side effects when they unknowingly took placebo pills.These side effects are real, and it appears may be mostly due to the psychological rather than the pharmacological effects of statins since symptoms were consistent when taking the placebo.

A medication derived from fish oil, containing the omega-3 fatty acids EPA and DHA, was evaluated in a large, international study of more than 13,000 people who had existing heart disease or who were at high risk of heart disease due to other medical conditions.The medication did not reduce the risk of cardiac events compared to a corn oil-based placebo in the STRENGTH trial.